Fulcrum Therapeutics (FULC)
US Market

Fulcrum Therapeutics (FULC) Stock Price & Analysis


FULC Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$3.07 - $24.79
Previous Close$3.14
Average Volume (3M)1.33M
Market Cap
Enterprise Value$4.43M
Total Cash (Recent Filing)$202.92M
Total Debt (Recent Filing)$13.42M
Price to Earnings (P/E)-1.3
May 17, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.49
Shares Outstanding61,666,789
10 Day Avg. Volume726,072
30 Day Avg. Volume1,330,705
Standard Deviation0.59
Financial Highlights & Ratios
Price to Book (P/B)3.39
Price to Sales (P/S)132.66
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-9.50
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.70
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.04
Price Target Upside224.44% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9



Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Fulcrum Therapeutics’s price range in the past 12 months?
Fulcrum Therapeutics lowest stock price was $3.06 and its highest was $24.79 in the past 12 months.
    What is Fulcrum Therapeutics’s market cap?
    Currently, no data Available
    When is Fulcrum Therapeutics’s upcoming earnings report date?
    Fulcrum Therapeutics’s upcoming earnings report date is May 17, 2023 which is in 53 days.
      How were Fulcrum Therapeutics’s earnings last quarter?
      Fulcrum Therapeutics released its earnings results on Mar 09, 2023. The company reported -$0.5 earnings per share for the quarter, missing the consensus estimate of -$0.49 by -$0.01.
        Is Fulcrum Therapeutics overvalued?
        According to Wall Street analysts Fulcrum Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Fulcrum Therapeutics pay dividends?
          Fulcrum Therapeutics does not currently pay dividends.
          What is Fulcrum Therapeutics’s EPS estimate?
          Fulcrum Therapeutics’s EPS estimate is -$0.46.
            How many shares outstanding does Fulcrum Therapeutics have?
            Fulcrum Therapeutics has 61,758,995 shares outstanding.
              What happened to Fulcrum Therapeutics’s price movement after its last earnings report?
              Fulcrum Therapeutics reported an EPS of -$0.5 in its last earnings report, missing expectations of -$0.49. Following the earnings report the stock price went down -23.003%.
                Which hedge fund is a major shareholder of Fulcrum Therapeutics?
                Among the largest hedge funds holding Fulcrum Therapeutics’s share is RA Capital Management. It holds Fulcrum Therapeutics’s shares valued at 69M.


                  Fulcrum Therapeutics Stock Smart Score

                  The Fulcrum Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Fulcrum Therapeutics

                  Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015 and is headquartered in Cambridge, MA.


                  Top 5 ETFs holding FULC

                  Market Value
                  Smart Score
                  Fidelity Nasdaq Composite Index ETF
                  Dimensional U.S. Equity ETF
                  Up to five ETFs with an Outperform Smart Score that hold FULC. The ETFs are listed according to market value of FULC within the ETF


                  Forecast EPS vs Actual EPS

                  Similar Stocks
                  Price & Change
                  Nuvation Bio
                  Phathom Pharmaceuticals
                  Atea Pharmaceuticals

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis